Recent developments include sponsor financial irregularities resulting in withdrawals from working capital, a reserved credit loss, and management changes with a new CEO appointment. The company also issued a convertible note as part of financing efforts related to the business combination.

• Between the IPO closing on September 26, 2025, and December 31, 2025, the sponsor withdrew $1,345,844 from the company’s working capital account, partially repaid to the sponsor, with an outstanding balance of $812,113 reserved as a credit loss [S1].
• The sponsor was unable to repay the outstanding balance, leading to the resignation and removal of CEO and Executive Chair Lynn Stockwell in February 2026 [S1].
• Roger Bendelac was appointed as the new Chief Executive Officer effective February 28, 2026 [S1].
• On March 11, 2026, the company issued an unsecured convertible note of $150,000 as part of a contemplated $1.4 million financing to cover expenses related to the business combination [S15][S16].

The company’s focus on reshoring pharmaceutical manufacturing aligns with growing concerns about U.S. supply chain vulnerabilities and drug shortages. Leveraging advanced manufacturing technologies and artificial intelligence could enable the post-combination company to produce cost-efficient, high-quality medications domestically, potentially capturing a significant addressable market including plant-based raw materials, APIs, and generics. The management team’s industry experience and networks may facilitate identifying and acquiring attractive targets and executing add-on acquisitions to accelerate growth.

The company currently has no operations or revenue and depends entirely on completing an initial business combination within 24 months. Failure to identify or consummate a suitable acquisition could lead to liquidation and dissolution. The sponsor’s recent financial irregularities and management turnover may raise governance and operational risks. The pharmaceutical industry is highly regulated and competitive, with potential legal, regulatory, and market risks. The company’s limited liquidity outside the trust account and reliance on third-party financing add financial risk. Competition from other SPACs and investors may limit acquisition opportunities or increase acquisition costs.

As a blank check company, Drugs Made In America Acquisition II Corp. currently has no operations or competitive advantages. Its potential moat would depend on the success of its initial business combination and the competitive positioning of the acquired pharmaceutical company or companies. The company’s strategy to focus on domestic pharmaceutical manufacturing and supply chain resilience addresses a recognized national security and market need, which could provide a differentiated position if executed effectively. However, the company faces competition from other SPACs and investors targeting similar acquisition opportunities, and the ultimate competitive advantages will depend on the acquired business’s defensible business model, technology, and market position.

• Execution Risk: The company must complete an initial business combination within 24 months or liquidate, which poses timing and execution challenges.
• Sponsor and Governance Risk: Recent financial irregularities involving the sponsor led to management changes, raising concerns about governance and sponsor reliability.
• Industry and Regulatory Risk: The pharmaceutical sector is highly regulated with complex legal and compliance requirements that may affect acquisition targets and operations.
• Financial and Liquidity Risk: Limited liquidity outside the trust account and reliance on additional financing may constrain operational flexibility and acquisition capacity.
• Cybersecurity Risk: Dependence on third-party digital technologies with limited internal cybersecurity resources exposes the company to potential cyber incidents.

• Drugs Made In America Acquisition II Corp. is a blank check company incorporated in the Cayman Islands for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses [S1].
• The company has not engaged in any operations nor generated any revenue to date and is considered a shell company with nominal assets consisting almost entirely of cash [S1].
• The company completed its initial public offering (IPO) on September 26, 2025, issuing 50,000,000 units at $10.00 per unit, generating gross proceeds of $500 million before expenses [S1].
• Simultaneously with the IPO, a private placement of 1,200,000 units was consummated with the sponsor and underwriter for $12 million [S1].
• The net proceeds from the IPO and private placement were placed in a trust account for the benefit of public shareholders, invested in U.S. government treasury obligations or money market funds [S1].
• The company has up to 24 months from the IPO closing to consummate an initial business combination, failing which it will redeem public shares and seek to liquidate and dissolve [S1].
• As of December 31, 2025, the company had cash and cash equivalents of $223,000 and current assets of $26,037,000, with current liabilities of $300,864,000, resulting in a current ratio of 0.09 and a cash ratio of 0, indicating limited liquidity outside the trust account [S1].
• The company’s net income for the fiscal year ended December 31, 2025, was $4,187,050, which includes a full reserve for an $812,113 expected credit loss related to an outstanding balance due from the sponsor that is unlikely to be recovered [S1].
• Between the IPO and December 31, 2025, the sponsor withdrew $1,345,844 from the company’s working capital account, partially repaid to the sponsor, with an outstanding balance reserved as a credit loss [S1].
• Following the sponsor’s inability to repay the balance due, the CEO and Executive Chair of the Board, Lynn Stockwell, resigned and was removed from all positions effective February 28, 2026; Roger Bendelac was appointed CEO [S1].
• The company’s acquisition strategy is to identify and acquire one or more companies in the pharmaceutical industry, focusing on reducing U.S. reliance on foreign pharmaceutical production by investing in domestic manufacturing technologies for critical drugs [S1].
• The post-business combination company aims to have end-to-end capabilities from plant-based raw material production (APIs) to drug manufacturing and distribution, targeting an addressable market including the $44 billion plant-based production segment, API market, and generic medications [S1].
• The business model intends to leverage advanced technology, including artificial intelligence and continuous manufacturing processes, to produce clean, cost-efficient medications in America, enhancing supply chain resilience and mitigating national health and security risks [S1].
• The company intends to acquire targets that are industry leaders with defensible business models, multiple growth avenues, sustainable financial profiles, and potential for add-on acquisitions, benefiting from the management team’s expertise and industry networks [S1].
• The company may use cash from the trust account, shares, debt, or a combination thereof to effectuate the initial business combination and may raise additional funds through private offerings if needed [S1].
• The company has issued a $150,000 unsecured convertible note as part of a contemplated $1.4 million financing to cover expenses related to the business combination [S15][S16].
• The company currently has two officers and no full-time employees prior to the initial business combination; management dedicates time as necessary to company affairs [S1].
• The company faces competition from other blank check companies and investors targeting similar acquisition opportunities in the pharmaceutical sector [S1].
• The company depends on third-party digital technologies and has limited cybersecurity resources, which could pose risks if incidents occur [S2].
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice [S1].